Skip to content ↓

Resources

Featured

PAREXEL and SHYFT Analytics Partner to Deliver Faster, More Dynamic Real-World Data Studies

PAREXEL and SHYFT Analytics Partner to Deliver Faster, More Dynamic Real-World Data Studies  SHYFT’s leading platform to become PAREXEL’s foundation for outcomes analysis in…

SHYFT to Develop a Launch Plan for Tetraphase Pharmaceuticals

Priya Sapra, SHYFT’s SVP, Product & Customer Engagement, talks to Pharmaceutical Commerce about SHYFT’s recent selection by Tetraphase Pharmaceuticals to support data and analytics for…

Novartis Partners with SHYFT to Support its Digital Transformation

NEW YORK and WALTHAM, Mass – July XX, 2018 — SHYFT Analytics, a Medidata Solutions (NASDAQ: MDSO) company, announced today that Novartis has…

Categories:
All
Articles
Events
Industry Insights
News
Webinars
White Papers

Recent Posts

Tetraphase Pharmaceuticals Selects SHYFT to Support Data and Analytics for Commercial Launch Readiness
News

Tetraphase Pharmaceuticals Selects SHYFT to Support Data and Analytics for Commercial Launch Readiness

Waltham, Mass. – SHYFT Analytics, recently acquired by Medidata Solutions to create the only Intelligent Platform for Life Sciences, announced Tetraphase Pharmaceuticals has selected its platform to support the anticipated commercial launch of eravacycline, its lead antibiotic candidate developed to address multidrug-resistant bacteria. The launch is subject to…

SHYFT Agrees to Acquisition by Medidata to Define the Future of Life Sciences
News

SHYFT Agrees to Acquisition by Medidata to Define the Future of Life Sciences

Medidata Defines the Future of Life Sciences with Acquisition of SHYFT Analytics   Leading the digital transformation of life sciences with artificial intelligence and advanced analytics NEW YORK — June 12, 2018 — Medidata (NASDAQ: MDSO) today announced that it has entered into a definitive…

Using Real-World Evidence to Optimize Clinical Trials
Industry Insights

Using Real-World Evidence to Optimize Clinical Trials

This pivotal new paper, which you can download HERE, describes how biopharmaceutical companies can better leverage existing real-world data (RWD) to improve the costs and efficiencies of R&D and accelerate the timelines of clinical trials without compromising the quality of evidence development, and instead greatly enhance trial feasibility, implementation,…

Join SHYFT at ISPOR 2018 in Baltimore
Events

Join SHYFT at ISPOR 2018 in Baltimore

The SHYFT team will be at ISPOR 2018 at the Baltimore Convention Center from May 21st to the 23rd. Stop by booth #245 and see a demo of our revolutionary Quantum RWE solution, capable of generating submission-ready studies in hours rather than months.